Lisinopril

Lisinopril is a pharmaceutical and healthcare brand produced under Germany-based generic drugmaker Ratiopharm. Since 2010, Ratiopharm has been wholly owned by Teva Pharmaceutical Industries Ltd., an israeli multinational pharmaceutical company headquartered in Tel Aviv. The boycott of Lisinopril stems directly from the israeli ownership, corporate nationality, and substantial financial backing its parent group provides to the israeli state.

Core Boycott Reasons:

• Teva Pharmaceutical Ownership & israeli Origin: In 2010, Teva acquired Ratiopharm for approximately €3.6 billion, integrating it as a key subsidiary of the israeli parent firm headquartered in Tel Aviv / Petah Tikva. Consequently, Lisinopril operates under the ultimate commercial ownership of israel's largest pharmaceutical enterprise.
• $750 Million Direct Tax Contribution to israel: In June 2024, Teva finalized a $750 million settlement agreement with the israel Tax Authority (ITA). Paying hundreds of millions of dollars in domestic corporate taxes annually, Teva directly funds the israeli government treasury and its public budgets.
• Legal Suppression of Boycott Campaigns: Teva and its corporate network have pursued aggressive legal action against Palestine solidarity organizers and boycott advocates in Europe (including lawsuits against EuroPalestine in France) in attempts to suppress consumer boycotts.
• Consolidated Revenue Inflow to israel: All commercial revenue and profits generated by Lisinopril flow through Ratiopharm into Teva's consolidated balance sheet, directly strengthening the israeli parent company.

Consequently, Lisinopril is subject to boycott due to its direct corporate integration under Ratiopharm and the israeli parent company Teva. For comprehensive documentation, please refer to the Ratiopharm brand page and the primary Teva Pharmaceutical boycott page.